Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP432520.RAFLN7jRAwvtXMw4rCa8zNyaqhbQwKLyj5Hu69sLY-zJA130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP432520.RAFLN7jRAwvtXMw4rCa8zNyaqhbQwKLyj5Hu69sLY-zJA130_assertion type Assertion NP432520.RAFLN7jRAwvtXMw4rCa8zNyaqhbQwKLyj5Hu69sLY-zJA130_head.
- NP432520.RAFLN7jRAwvtXMw4rCa8zNyaqhbQwKLyj5Hu69sLY-zJA130_assertion wasGeneratedBy ECO_0000203 NP432520.RAFLN7jRAwvtXMw4rCa8zNyaqhbQwKLyj5Hu69sLY-zJA130_provenance.
- NP432520.RAFLN7jRAwvtXMw4rCa8zNyaqhbQwKLyj5Hu69sLY-zJA130_assertion wasDerivedFrom befree-2016 NP432520.RAFLN7jRAwvtXMw4rCa8zNyaqhbQwKLyj5Hu69sLY-zJA130_provenance.
- NP432520.RAFLN7jRAwvtXMw4rCa8zNyaqhbQwKLyj5Hu69sLY-zJA130_assertion SIO_000772 14976243 NP432520.RAFLN7jRAwvtXMw4rCa8zNyaqhbQwKLyj5Hu69sLY-zJA130_provenance.
- NP432520.RAFLN7jRAwvtXMw4rCa8zNyaqhbQwKLyj5Hu69sLY-zJA130_assertion evidence source_evidence_literature NP432520.RAFLN7jRAwvtXMw4rCa8zNyaqhbQwKLyj5Hu69sLY-zJA130_provenance.
- NP432520.RAFLN7jRAwvtXMw4rCa8zNyaqhbQwKLyj5Hu69sLY-zJA130_assertion description "[The ABL inhibitor Imatinib (Gleevec, STI571) has remarkable efficacy for treating chronic phase CML, and FLT3 inhibitors (e.g., PKC412) show similar promise in preclinical studies.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP432520.RAFLN7jRAwvtXMw4rCa8zNyaqhbQwKLyj5Hu69sLY-zJA130_provenance.